Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Study: Nursing Shortages Require Workforce Policy Solutions, Not Recruitment Campaigns Alone9.9.2026 15:01:00 CEST | Press release
Why people choose nursing, and why they leave, comes down to the same factors PHILADELPHIA, PA / ACCESS Newswire / September 9, 2026 / The global nursing shortage cannot be solved simply by encouraging more people to enter the profession, according to a new evidence brief from the Global Nursing Workforce Centre (GNWC), a joint initiative of the International Council of Nurses (ICN) and TruMerit®. Drawing on research from 42 countries, the brief, The Attractiveness of Nursing for Prospective and Current Nursing Students, finds that the factors influencing people to choose nursing are often the same ones that determine whether they stay. Working conditions, compensation, professional respect, career development opportunities, workplace experiences, and the ability to provide quality care all shape nursing attractiveness to current nurses as well as potential recruits. The findings suggest that countries seeking to strengthen their nursing workforce must focus not only on recruitment, bu
Leggett Dynamics Showcases Award-Finalist Innovations at Automotive News Congress in Detroit9.9.2026 13:00:00 CEST | Press release
Mid-Class Massage System & Smart Brushless Motor Named Finalist For 2026 Automotive News PACE & PACE Pilot Awards DETROIT, MI / ACCESS Newswire / September 9, 2026 / Leggett Dynamics will showcase two next-generation comfort and motion technologies at the 50th Automotive News Congress, September 29-30 in Detroit, Michigan. Both innovations have been named finalists for 2026 Automotive News awards, recognizing the company's commitment to developing innovative comfort and motion solutions that address the evolving needs of automakers and consumers. Leggett Dynamics' Mid-Class Massage System has been named a finalist for the 2026 Automotive News PACE Award, while the company's Smart Brushless Motor has been named a finalist for the 2026 Automotive News PACE Pilot Award. During the 50th Automotive News Congress event, attendees are invited to visit Leggett Dynamics' showcase to explore both technologies firsthand and connect with the team behind their development. The showcase will offer a
IXOPAY Launches Agentic Suite to Help Merchants Support Agentic Commerce and Automate Payment Workflows9.9.2026 12:00:00 CEST | Press release
Flexible, Protocol-Agnostic Suite Helps Merchants Support Agentic Commerce, Preserve Transaction Context and Accelerate Payment Workflows With Secure AI Access DALLAS, TX / ACCESS Newswire / September 9, 2026 / IXOPAY, a leader in payment infrastructure enabling fluid commerce, today announced the launch of the IXOPAY Agentic Suite, a flexible set of tools designed to help merchants prepare for both new agentic buying experiences and the growing role of AI in payment operations. The suite includes Payment Agent, which provides protocol-agnostic connectivity between agentic shopping experiences and existing payment infrastructure; Universal Tokens to preserve transaction context so merchants can confidently participate in agentic commerce while reducing risk; and Model Context Protocol (MCP) Server, which gives approved AI assistants secure and governed access to payment and tokenization capabilities. Together, the suite gives merchants a faster and more flexible way to launch new buyin
Learnis: A New International Network for Transformative Education is Born.8.9.2026 23:05:00 CEST | Press release
Three groups of companies from Italy, Spain and the United States unite in a new corporate network structure, strong of a 20-year shared method that converges under one masterbrand - Learnis, Your transformative education. MILAN, IT / ACCESS Newswire / September 8, 2026 / A new corporate structure brings together Genio Net, the Italian business network directed by Massimo De Donno; Crecimiento Personal SL, the company headed by Giacomo Navone as the franchisor of the Spanish network; and Genius in 21 Days LLC, founded in the United States by Stephanie Turconi and Cosimo Intermite. Across the three countries, the group runs more than 50 learning centers, working with certified instructors and tutors, and reaching over 5,000 participants each year with its immersive courses, training paths and publications, with a focus on personalized study methods and learning. The group has chosen to introduce itself publicly on September 8, 2026, the International Literacy Day. Promoted by UNESCO to
TripGift Launches Its Next-Generation Global Travel Value Platform8.9.2026 14:30:00 CEST | Press release
The 103-currency platform brings together global travel gift cards, rewards, incentives, programmable promotional vouchers and travel redemption across more than 180 countries. NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / TripGift, the multi-award-winning global Travel Value Platform, today announced the launch of its next-generation platform, expanding how organizations can integrate travel value into customer, partner and employee programs. Building on TripGift's established global travel gifting and redemption capabilities, the platform brings together its eight proprietary travel gift brands, Travel Value API, Purpose-Bound Promotional Vouchers and travel redemption platform. TripGift's market-leading platform enables travel gift cards to be purchased in 103 currencies and redeemed across more than 180 countries, with access to 2.9 million+ travel and lifestyle booking options, including 2.8 million accommodations, 600 airlines, 30,000 mobility locations, 50,000 tours
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom